0 CHECKOUT

Recurrent Malignant Glioma - Pipeline Review, H2 2015

  • ID: 3384517
  • July 2015
  • 61 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Eisai Co., Ltd.
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.
  • MORE

‘Recurrent Malignant Glioma - Pipeline Review, H2 2015’, provides an overview of the Recurrent Malignant Glioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Eisai Co., Ltd.
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Recurrent Malignant Glioma Overview

Therapeutics Development

Pipeline Products for Recurrent Malignant Glioma - Overview

Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis

Recurrent Malignant Glioma - Therapeutics under Development by Companies

Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes

Recurrent Malignant Glioma - Pipeline Products Glance

Clinical Stage Products

Recurrent Malignant Glioma - Products under Development by Companies

Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes

Recurrent Malignant Glioma - Companies Involved in Therapeutics Development

Amgen Inc.

AstraZeneca Plc

Eisai Co., Ltd.

MediGene AG

Tiziana Life Sciences Plc

ZIOPHARM Oncology, Inc.

Recurrent Malignant Glioma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Ad-RTS-IL-12 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Carboxyamidotriazole Orotate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Refractory Gliomas - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dendritic Cell Therapy for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dendritic Cell Therapy for Recurrent Malignant Glioma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

disufenton sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DNX-2401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

G-207 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

irofulven - Drug Profile

Product Description

Mechanism of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rilotumumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recurrent Malignant Glioma - Recent Pipeline Updates

Recurrent Malignant Glioma - Dormant Projects

Recurrent Malignant Glioma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Recurrent Malignant Glioma, H2 2015

Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Recurrent Malignant Glioma - Pipeline by Amgen Inc., H2 2015

Recurrent Malignant Glioma - Pipeline by AstraZeneca Plc, H2 2015

Recurrent Malignant Glioma - Pipeline by Eisai Co., Ltd., H2 2015

Recurrent Malignant Glioma - Pipeline by MediGene AG, H2 2015

Recurrent Malignant Glioma - Pipeline by Tiziana Life Sciences Plc, H2 2015

Recurrent Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Recurrent Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2015

Recurrent Malignant Glioma - Dormant Projects, H2 2015

Recurrent Malignant Glioma - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Recurrent Malignant Glioma, H2 2015

Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Amgen Inc.
AstraZeneca Plc
Eisai Co., Ltd.
MediGene AG
Tiziana Life Sciences Plc
ZIOPHARM Oncology, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.